Jun 9, 2014
iCo Therapeutics Announces Top-Line Primary Endpoint Data from iCo-007 Phase 2 iDEAL Study in Diabetic Macular Edema
May 29, 2014
iCo Therapeutics Announces First Quarter 2014 Financial Results
Apr 29, 2014
iCo Therapeutics Announces Poster Presentation at ARVO
View All News (+)
iCo Therapeutics Inc. (ICO: TSX-V, ICOTF:OTCQX) is a biotechnology company. By focusing efforts on development instead of research, iCo's business model aims to acquire the rights to drugs that are either off-patent, currently approved or near commercialization and develop them by redosing or reformulating them for new or expanded labels. Management strength is supported by an impressive group of Directors and Advisors.
There is a significant decrease in development risk associated with targeting existing drugs, including:
- Reduced risk of adverse events since clinical testing and systemic use in humans has already been established.
- Scale-up and manufacturing issues have already been addressed since clinical grade material has been made.
- The target and mechanism of action has been identified.
iCo Therapeutics is developing iCo-007, a second generation antisense inhibitor targeting C-raf kinase messenger ribonucleic acid (mRNA), for the treatment of retinal neovascular diseases such as diabetic retinopathy (including diabetic macular edema). These conditions are characterized by new blood vessel growth and increased vascular permeability. Drug products that prevent the growth of new blood vessels and inhibit increased vascular permeability may have the potential to treat neovascular diseases, including diabetic retinopathy and diabetic macular edema. Read More +
iCo-008 (also known as Bertilimumab or CAT-213) is a human immunoglobulin monoclonal antibody targeting eotaxin-1, a member of the chemokine family of proteins, that acts as messenger molecules between the cells of the immune system.
Eotaxin-1 is released by various cells, including eosinophils, epithelial cells, fibroblasts, endothelial cells, T-lymphocytes, monocytes and macrophages. During an allergic response the levels of eotaxin-1 are elevated. This attracts eosinophils, a type of white blood cell, into tissues where they can degranulate causing tissue damage that occurs in a variety of allergic disorders. This condition, known as eosinophilia, can occur in a number of disorders, such as allergic ocular disease of conjunctiva and cornea (conjunctivitis and keratoconjunctivitis), asthma, allergic rhinitis, atopic dermatitis, and other inflammatory disorders, such as inflammatory bowel disease and Crohn's disease. Read More +
Oral Amphotericin B Delivery System
iCo Therapeutics owns the worldwide exclusive rights to an oral Amphotericin B delivery system for life-threatening infections. The drug delivery technology also has the potential to reprofile other IV administered drugs to the oral route of administration.
Amphotericin B (AmpB), the gold standard for systemic antifungal drugs, is one example of a well established, highly efficacious systemic antifungal drug that has a 50 year history of intravenous therapy. AmpB formulated as a micellar dispersion (Fungizone® FZ) for IV use, remains one of the most effective agents in the treatment of systemic fungal infections, yet no oral formulations are currently commercially available. Read More +
Alliances & Global Licensing
iCo is actively looking to identify and acquire the rights to products that have a previous clinical history with potential for ophthalmic uses. iCo then employs various drug delivery technologies, re-doses or reformulates these existing products in order to enable ocular administration and gain additional intellectual property coverage for the product. This strategy enables partners to maximize the value of their existing assets with minimal risk of cross use / cross pricing issues.
iCo Therapeutics is currently engaged in partnership arrangements with organizations that include Isis Pharmaceuticals, MedImmune, Immune Pharmaceuticals, AstraZeneca and the University of British Columbia.
iCo Therapeutics acquired the exclusive, world-wide rights from partner Isis Pharmaceuticals Inc., to develop and commercialize iCo-007 for all disease indications.
iCo has a research collaboration agreement with JDRF, the worldwide leader for research to cure, treat, and prevent type 1 diabetes (T1D), to support the previously announced Phase 2 investigator sponsored clinical trial investigating iCo-007 in Diabetic Macular Edema (DME).
From partner MedImmune (a division of Astra Zeneca), iCo Therapeutics acquired the exclusive, world-wide rights to develop and commercialize iCo-008 for all disease indications. In 2010, iCo granted Immune Pharmaceuticals an option to an exclusive license for the development and commercialization rights to the systemic uses of iCo-008. Immune Pharmaceuticals licensed the systemic rights to iCo-008 in June 2011. iCo retained worldwide exlcusive rights to all ocular applications of iCo-008. The partnership with the University of British Columbia resulted in the acquisition of the exclusive, worldwide rights to a novel oral formulation for Amphotericin B to be used for potential systemic fungal and parasitic infections.